Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
slno · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Soleno Therapeutics, Inc. (SLNO) measures how much investors pay for each dollar of the company's trailing earnings. SLNO's current PE ratio of 28.75x is calculated by dividing its stock price of $53.01 by its TTM earnings per share of $1.84. −75.6% discount vs 5Y avg 117.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Soleno Therapeutics, Inc.You SLNO | $2.8B | 28.75x | — | $1.84 |
 Ascentage Pharma Group International AAPG | $1.6B | N/A | — | -$13.58 |
 Apogee Therapeutics, Inc. APGE | $5.1B | N/A | — | -$4.22 |
 Celcuity Inc. CELC | $4.2B | N/A | — | -$3.37 |
 Centessa Pharmaceuticals plc CNTA | $6.1B | N/A | — | -$1.46 |
 Dyne Therapeutics, Inc. DYN | $2.8B | N/A | — | -$3.47 |
 Mirum Pharmaceuticals, Inc. MIRM | $4.7B | N/A | — | -$0.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 117.86x | $0.39 | — | |
2024-12-31 FY2024 | — | $-4.38 | — | |
2023-12-31 FY2023 | — | $-2.36 | — | |
2022-12-31 FY2022 | — | $-2.87 | — | |
2021-12-31 FY2021 | — | $-5.81 | — | |
2020-12-31 FY2020 | — | $-5.90 | — | |
2019-12-31 FY2019 | — | $-13.52 | — | |
2018-12-31 FY2018 | — | $-9.54 | — | |
2017-12-31 FY2017 | — | $-26.18 | — | |
2016-12-31 FY2016 | — | $-58.35 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Soleno Therapeutics, Inc. (SLNO) measures how much investors pay for each dollar of the company's trailing earnings. SLNO's current PE ratio of 28.75x is calculated by dividing its stock price of $53.01 by its TTM earnings per share of $1.84.
Frequently asked questions
SLNO pe ratio · 6 questionsSLNO's current PE ratio is 28.75x as of 2026-06-08, based on a stock price of $53.01 and TTM EPS of $1.84. Data sourced from Financial Modeling Prep via SLNO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Soleno Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08